Long term follow-up of Phase 3 AZURE prospective/retrospective study of MAFTest® in Journal of Bone Oncology demonstrates the survival benefit effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer

Inbiomotion SL today announced the publication of the results of the long-term follow-up of Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAFTest® in the September issue of Journal of Bone Oncology.